GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+20.32%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$277M
AUM Growth
+$277M
(+4.8%)
Cap. Flow
-$4.64M
Cap. Flow
% of AUM
-1.67%
Top 10 Holdings %
Top 10 Hldgs %
51.48%
Holding
69
New
14
Increased
24
Reduced
14
Closed
11
Top Buys
| 1 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$6.96M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
$6.89M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$5.78M |
| 4 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$4.01M |
| 5 |
Akero Therapeutics
AKRO
|
$3.97M |
Top Sells
| 1 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$8.4M |
| 2 |
Axsome Therapeutics
AXSM
|
$8.26M |
| 3 |
Pfizer
PFE
|
$8.16M |
| 4 |
Johnson & Johnson
JNJ
|
$7.75M |
| 5 |
TG Therapeutics
TGTX
|
$6.83M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
TG Therapeutics
TGTX
$4.65B
| $20.5M | 6.77% | 825,000 -275,000 | -25% | -$6.83M |
|
|
2
MoonLake Immunotherapeutics
MLTX
$3.54B
| $16.8M | 5.56% | 330,000 +135,000 | +69% | +$6.89M |
|
|
3
Akero Therapeutics
AKRO
$3.74B
| $16.8M | 5.55% | 360,000 +85,000 | +31% | +$3.97M |
|
4
Apellis Pharmaceuticals
APLS
$3.48B
| $16.4M | 5.41% | 180,000 +15,380 | +9% | +$1.4M |
|
5
Vaxcyte
PCVX
$4B
| $14M | 4.62% | 280,000 +55,000 | +24% | +$2.75M |
|
|
RVNC
6
DELISTED
Revance Therapeutics, Inc.
RVNC
| $13.3M | 4.39% | 525,000 +275,000 | +110% | +$6.96M |
|
|
7
Madrigal Pharmaceuticals
MDGL
$9.76B
| $12.7M | 4.19% | 55,000 +25,000 | +83% | +$5.78M |
|
8
Amylyx Pharmaceuticals
AMLX
$836M
| $11.9M | 3.92% | 550,000 +75,000 | +16% | +$1.62M |
|
9
Viking Therapeutics
VKTX
$3.04B
| $10.5M | 3.48% | 650,000 +50,000 | +8% | +$811K |
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $9.73M | 3.21% | 85,000 +25,000 | +42% | +$2.86M |
|
11
Ascendis Pharma
ASND
$11.8B
| $8.93M | 2.95% | 100,000 -10,000 | -9% | -$893K |
|
|
RETA
12
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $8.67M | 2.86% | 85,000 +15,000 | +21% | +$1.53M |
|
|
13
Axsome Therapeutics
AXSM
$6.05B
| $7.9M | 2.61% | 110,000 -115,000 | -51% | -$8.26M |
|
14
Syndax Pharmaceuticals
SNDX
$1.41B
| $7.33M | 2.42% | 350,000 +25,000 | +8% | +$523K |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.23M | 2.39% | 200,000 +60,000 | +43% | +$2.17M |
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $7.12M | 2.35% | 185,000 -15,000 | -8% | -$578K |
|
17
Cogent Biosciences
COGT
$1.69B
| $6.81M | 2.25% | 575,000 +25,000 | +5% | +$296K |
|
18
Protagonist Therapeutics
PTGX
$3.67B
| $6.21M | 2.05% | 225,000 | – | – |
|
19
Viridian Therapeutics
VRDN
$1.5B
| $5.71M | 1.88% | 240,000 +65,000 | +37% | +$1.55M |
|
20
Biomea Fusion
BMEA
$116M
| $4.17M | 1.38% | 190,000 +70,000 | +58% | +$1.54M |
|
21
Incyte
INCY
$16.5B
| $4.05M | 1.34% | 65,000 -10,000 | -13% | -$623K |
|
|
ONC
22
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $4.01M | 1.32% | +22,500 | New | +$4.01M |
|
|
AMAM
23
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $3.92M | 1.29% | 238,225 -11,775 | -5% | -$194K |
|
24
Vir Biotechnology
VIR
$686M
| $3.68M | 1.21% | +150,000 | New | +$3.68M |
|
|
ALPN
25
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $3.57M | 1.18% | 347,432 +147,432 | +74% | +$1.52M |
|